NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $23.88 -0.88 (-3.55%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends About Arcturus Therapeutics Stock (NASDAQ:ARCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$23.51▼$25.3850-Day Range$18.08▼$25.4852-Week Range$17.52▼$45.00Volume215,611 shsAverage Volume486,807 shsMarket Capitalization$643.14 millionP/E RatioN/ADividend YieldN/APrice Target$71.40Consensus RatingBuy Company OverviewArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More… Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. Arcturus Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks59th Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 464th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.60) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.17% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 2.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth.Dividend SustainabilityBased on EPS estimates, Arcturus Therapeutics will have a dividend payout ratio of 357.50% in the coming year. This indicates that Arcturus Therapeutics may not be able to sustain their current dividend.Read more about Arcturus Therapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.17% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 2.79%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.77 News SentimentArcturus Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest8 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Stock News HeadlinesArcturus shares hold with Buy rating on Japan vaccine progressOctober 4 at 5:04 PM | uk.investing.comPositive Outlook for Arcturus Therapeutics’ Vaccine Production and Distribution Spurs Buy RatingOctober 4 at 5:04 PM | markets.businessinsider.comRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...October 6, 2024 | Behind the Markets (Ad)Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.5%October 2, 2024 | americanbankingnews.comBuy Rating Justified by Arcturus Therapeutics’ Market Potential and Strong Vaccine EfficacyOctober 2, 2024 | markets.businessinsider.comArcturus Therapeutics: A Strong Buy on Superior Vaccine Efficacy and Market PotentialOctober 1, 2024 | markets.businessinsider.comArcturus Therapeutics' (ARCT) Buy Rating Reiterated at HC WainwrightOctober 1, 2024 | americanbankingnews.comSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationSeptember 30, 2024 | prnewswire.comSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of 2024. Since then, ARCT stock has decreased by 24.3% and is now trading at $23.88. View the best growth stocks for 2024 here. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings data on Monday, August, 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($1.85) by $1.21. The biotechnology company had revenue of $49.86 million for the quarter, compared to analysts' expectations of $21 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative trailing twelve-month return on equity of 25.47%. When did Arcturus Therapeutics' stock split? Arcturus Therapeutics shares split on the morning of Saturday, January 1st 2000. The 7-1 split was announced on Saturday, January 1st 2000. The newly created shares were distributed to shareholders after the market closes on Thursday, November 16th 2017. An investor that had 100 shares of stock prior to the split would have 700 shares after the split. Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK) and NVIDIA (NVDA). Company Calendar Last Earnings8/05/2024Today10/05/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$71.40 High Stock Price Target$90.00 Low Stock Price Target$48.00 Potential Upside/Downside+199.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-41.21% Pretax Margin-42.27% Return on Equity-25.47% Return on Assets-16.25% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual Sales$147.03 million Price / Sales4.37 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book2.29Miscellaneous Outstanding Shares26,932,000Free Float23,215,000Market Cap$643.14 million OptionableOptionable Beta2.61 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ARCT) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.